For this reason, the pan-LOX inhibitor Nordy [303,310], 5-LOX inhibitors such as caffeic acid [307], A861 [311], AA-863, and U-60,257 (pyriprost) [312], LTA4H inhibitors such as bestatin [311], and CysLTR1 and CysLTR2 receptor inhibitors such as montelukast and zafirlukast [313] have anti-tumor properties against GBM and inhibit proliferation. Here, LOX is linked to neoplasm.